Continue Reading
Full article on Yahoo Finance
Liminatus Pharma Announces Transfer to Nasdaq Capital Market and Extension to Regain Compliance with Minimum Bid Price Requirement
Market Intelligence Analysis
AI-Powered 60% FREE-ANALYSIS-RULE-BASED-ANALYSIS
Why This Matters
Analysis of stock market developments showing bullish sentiment.
Sentiment
Bullish
AI Confidence
60%
Time Horizon
Short Term
Affected Symbols
Article Context
Note: This is a brief excerpt for context. Click below to read the full article on the original source.
FULLERTON, Calif., Aug. 13, 2026 (GLOBE NEWSWIRE) -- Liminatus Pharma, Inc. (Nasdaq: LIMN) (“Liminatus” or the “Company”), a biopharmaceutical company developing novel therapies for cancer and other serious diseases, today announced that its common stock was transferred from the Nasdaq Global Market to the Nasdaq Capital Market, effective August 4, 2026, and that the Nasdaq Hearings Panel (the “Panel”) has granted the Company additional time to demonstrate compliance with Nasdaq’s minimum bid pr
AI Evidence
What our AI predicted from this news — tracked and scored against the real market move.
Pending evaluation
- free-analysis-rule-based-analysis NASDAQ Bullish Confidence: 60%
Logged at publication, scored automatically once the window closes — never edited.
AI Breakdown
Summary
Analysis of stock market developments showing bullish sentiment.
Time Horizon
Short Term
Original article published by
Yahoo Finance
on August 13, 2026.
Analysis and insights provided by AnalystMarkets AI.
Analysis and insights provided by AnalystMarkets AI.